32
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6812L |
Cyclo(-RGDfK) TFA
|
Integrin | Cytoskeletal Signaling |
Cyclo(-RGDfK) TFA 是一种选择性整合素αvβ3的有效抑制剂,其IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。 | |||
T6812 |
Cyclo(-RGDfK)
Cyclo (-RGDfK) |
Integrin | Cytoskeletal Signaling |
Cyclo(-RGDfK) (Cyclo (-RGDfK)) 是一种选择性整合素αvβ3的有效抑制剂,IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。 | |||
TP1474 |
LXW7
|
Integrin | Cytoskeletal Signaling |
LXW7 是一种整合素αvβ3抑制剂,是含 Arg-Gly-Asp (RGD) 的环状肽,对αvβ3整联蛋白具有很高的结合亲和力,IC50为 0.68 μM。它可增强 VEGFR-2 磷酸化和 ERK1/2 活化,具有抗炎活性。 | |||
TP1879L1 |
P11 acetate
|
Integrin | Cytoskeletal Signaling |
P11 acetate 是一种整合素 αvβ3-玻连蛋白相互作用拮抗剂 (IC50 = 2.74 nM)。 | |||
T6813 |
Cyclo(RGDyK) trifluoroacetate
Cyclo(RGDyK) |
Integrin | Cytoskeletal Signaling |
Cyclo(RGDyK) trifluoroacetate 是一种选择性αVβ3整联蛋白抑制剂,IC50为 20 nM。 | |||
T6657 |
SB273005
|
Integrin | Cytoskeletal Signaling |
SB273005 是一种有效的整合素抑制剂,对 αvβ3 受体和 αvβ5 受体的 Ki 分别为 1.2 nM 和 0.3 nM。 | |||
T2494 |
Cilengitide
西仑吉肽,EMD 121974 |
Integrin; Autophagy | Autophagy; Cytoskeletal Signaling |
Cilengitide (EMD 121974) 是一种有效的 αvβ3/5 受体整合素抑制剂,可抑制 ανβ3和 ανβ5与玻连蛋白结合,IC50值分别为 4 和 79 nM。 | |||
TP1459L |
Gly-Arg-Gly-Asp-Ser acetate(96426-21-0 free base)
|
Integrin | Cytoskeletal Signaling |
Gly-Arg-Gly-Asp-Ser acetate(96426-21-0 free base) 是一种源自纤连蛋白的细胞结合区域的细胞结合蛋白结构域。 | |||
T16085 |
MK-0429
L-000845704 |
Others | Others |
MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM). | |||
TP2148 |
LXW7 TFA (1313004-77-1 free base)
LXW7 TFA |
Integrin | Cytoskeletal Signaling |
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2. | |||
TQ0250 |
CWHM-12
|
Integrin | Cytoskeletal Signaling |
CWHM-12 是 αV 整合素的有效抑制剂,抑制αvβ8、αvβ3、αvβ6和αvβ1,IC50 为 0.2、0.8、1.5 和 1.8 nM。 | |||
TP2390 |
Maraciclatide
NC-100692,NC 100692,NC100692 |
||
Maraciclatide is a radiopharmaceutical targeting αvβ3 integrin. | |||
TP1879 |
HSDVHK-NH2
P11 |
||
Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic. | |||
T8726 |
Cyclo(RGDyK)
|
Integrin | Cytoskeletal Signaling |
Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM. | |||
T15584 |
Integrin Antagonists 27
|
Others | Others |
Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist. It has a binding affinity of 18 nM and as a novel anticancer agent. | |||
T69460 | TSRI265 | ||
TSRI265 is a novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo. | |||
T11663 | Integrin-IN-2 | Others | Others |
Integrin-IN-2 is an orally bioavailable pan αv integrin inhibitor.Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively. | |||
T68462 |
D-Ornithine lactam
|
||
D-Ornithine lactam is a building block. It has been used in the synthesis of hepatitis C virus non-structural protein 5B inhibitors, as well as αVβ3 integrin receptor antagonists. | |||
T6806 |
Cilengitide TFA
|
Integrin; Autophagy | Autophagy; Cytoskeletal Signaling |
Cilengitide TFA 是一种选择性的 αvβ3和 αvβ5受体整合素抑制剂,IC50分别为 4 nM 和 79 nM。对 GP IIb/IIIa 的选择性约为 10 倍。 | |||
T10920 |
Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
|
Others | Others |
Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3. | |||
T76068 |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
|
||
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA 是一种环状RGD多肽, 对αvβ3有高亲和性,能干扰细胞整合素之间的相互作用。此化合物能抑制胚胎干细胞(ESC)的多潜能性基因表达,并可在体内减少mESC的致瘤潜力,因此适用于肿瘤研究领域。 | |||
T75724 |
LXW7 TFA
|
||
LXW7 TFA, 包含 Arg-Gly-Asp (RGD) 的环状肽,作为整合素αvβ3抑制剂,展示出对αvβ3整联蛋白高度的结合亲和力,其IC50值为0.68 μM。此外,LXW7 TFA 能够促进 VEGFR-2 磷酸化和 ERK1/2 激活,显示出抗炎活性。 | |||
T82516 |
E(c(RGDfK))₂
|
||
E(c(RGDfK))是一种针对αvβ3整联蛋白的特异性结合片段,表现出对肿瘤的靶向作用。在人卵巢癌OVCAR-3异种移植肿瘤模型中,该化合物的摄取有所提升,适用于癌症研究领域。 | |||
T75990 |
Cyclo(Arg-Gly-Asp-D-Phe-Val)
|
||
Cyclo(Arg-Gly-Asp-D-Phe-Val) 为一种整合素αvβ3抑制剂,具有抗肿瘤活性,并可用于急性髓系白血病的研究。 | |||
T76807 | Etaracizumab | ||
Etaracizumab (LM 609),一种αvβ3整合素IgG1单克隆抗体,具有抑制血管生成和黑色素瘤生长的作用,可用于抗癌研究。 | |||
T75835 |
HSDVHK-NH2 TFA
|
||
HSDVHK-NH2 TFA 作为一种整合素 αvβ3-玻璃体结合蛋白的互作拮抗剂,其IC50值达到1.74 pg/mL (2.414 pM)。 | |||
TP1974 |
Obtustatin
|
||
Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitum | |||
T83736 |
RTDLDSLRTYTL TFA
|
||
RTDLDSLRTYTL是一种αVβ6整合素配体。它选择性地抑制纤维连接蛋白与αVβ6整合素的结合,相比之下,对于纤维连接蛋白与αVβ3或αVβ5以及纤维蛋白原与αIIβ3的结合则几乎不产生影响(IC50分别为0.02, >50, >50, 和 >50 µM)。此外,RTDLDSLRTYTL还能以浓度依赖的方式抑制HT-29结肠癌细胞与纤维连接蛋白的结合。 | |||
T74400 | TC113 | ||
TC113是一种与c(RGDyK)偶联的Gemcitabine。它通过整合素αvβ3可被A549细胞内化。此外,TC113对WM266.4和A549细胞表现出显著的抗增殖效果。 | |||
T78064 |
Synstatin (92-119)
SSTN92-119 |
Integrin | Cytoskeletal Signaling |
Synstatin (92-119)为一种抗肿瘤化合物,它能够抑制血管生成与癌细胞侵袭,通过下调整合素αvβ3,降低VEGF与FGF-2的活化。 | |||
TP2098 |
Echistatin
Echistatin, α1 isoform |
||
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) | |||
T75761 |
Gly-Arg-Gly-Asp-Ser TFA
GRGDS TFA |
||
Gly-Arg-Gly-Asp-Ser (TFA) 是一种与糖蛋白和骨桥蛋白在细胞结合域中起作用的五肽。该化合物能够与整合素整联蛋白受体αvβ3和αvβ5结合,其IC50值分别约为5 μM和6.5 μM。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36715 |
Tetrac
Tetraiodothyroacetic acid,3,3',5,5'-Tetraiodothyroacetic acid |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tetrac (Tetraiodothyroacetic acid)是L-甲状腺素(T4)的衍生物,是一种甲状腺整合素受体拮抗剂。Tetrac通过阻断EGFR介导的结直肠癌细胞信号传导来诱导抗增殖。Tetrac 可阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3)在细胞表面甲状腺素整合素 αvβ3 受体上的作用。Tetra 具有抗血管生成、抗肿瘤活性和促凋亡活性。 | |||
T36295 | Echistatin TFA | ||
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1[1][2][3][4]. [1]. J Musial, et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation. 1990 Jul;82(1):261-73.[2]. ... |